HCG 5000 IU

HCG 5000 IU is FDA-approved for specific medical indications: prepubertal cryptorchidism not due to anatomical obstruction, selected cases of hypogonadotropic hypogonadism in males, and induction of ovulation and pregnancy in anovulatory infertile women who have been pretreated with human menotropins. HCG is not approved for weight loss or athletic performance enhancement.

FDA-approved dosing varies by indication. For cryptorchidism, 4,000–5,000 USP units three times weekly or every other day is referenced. For hypogonadotropic hypogonadism in males, 500–1,000 USP units three times weekly is referenced. In non-medical bodybuilding contexts, 250–500 IU every other day is sometimes referenced, but this is not FDA-approved and lacks clinical validation.

HCG is not a standard component of post-cycle therapy. In non-medical bodybuilding contexts, some references suggest HCG may be used during a cycle or in the weeks following the last testosterone injection, prior to starting SERM-based PCT. However, this use is not FDA-approved. Agents such as Clomid or Tamoxifen are more commonly referenced for PCT purposes.

HCG acts virtually identically to pituitary luteinizing hormone (LH). It stimulates the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone. In males, this leads to androgen production and may stimulate testicular descent when no anatomical impediment is present.

The time required for HCG to produce effects depends on the indication and individual factors. For testicular descent in cryptorchidism, response may be observed within weeks of starting therapy, though in most cases the response is temporary. For androgen production, the effects are mediated through Leydig cell stimulation and depend on the dosing regimen.

There is no single treatment that is universally best. HCG is FDA-approved for selected cases of hypogonadotropic hypogonadism in males. Other treatments such as testosterone replacement therapy may be more appropriate for different types of hypogonadism. The appropriate choice depends on the specific diagnosis and should be determined by a qualified healthcare professional.

HCG and testosterone are different compounds with distinct mechanisms. HCG is a glycoprotein hormone that stimulates Leydig cells to produce testosterone endogenously, while Testosterone Enanthate directly provides exogenous testosterone. HCG acts upstream of testosterone production, whereas exogenous testosterone bypasses the body's own production pathway.

HCG is a glycoprotein hormone that directly stimulates Leydig cells to produce testosterone. Clomid is a selective estrogen receptor modulator that acts on the hypothalamus and pituitary to increase gonadotropin secretion. These are fundamentally different mechanisms of action.

5000 IU is the total vial content, not a single dose. The appropriate dose depends on the medical indication and is determined by a physician. For cryptorchidism, 4,000–5,000 USP units per injection is referenced. It is important to distinguish a vial content from a dose; the 5000 IU label indicates the total hormone content per vial.

HCG 5000 IU is labeled at 5000 IU of Human Chorionic Gonadotropin per vial. It is supplied as a lyophilized powder in a 2 mL vial.

Yes. A published laboratory report dated September 10, 2024 measured HCG 5000 IU at 5196 IU, equivalent to 103.92% of its 5000 IU label claim. The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report.

No. The FDA has explicitly stated that HCG has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. There is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, causes a more attractive or "normal" distribution of fat, or decreases hunger and discomfort associated with calorie-restricted diets. HCG is not approved for weight loss.